Doctors have begun trialing the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.
The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.
As a company working on drug delivery solutions for oligonucleotides, we hold our breath and watch carefully how this goes.
World-first lung cancer vaccine trials launched across seven countries | Lung cancer | The Guardian
